Multi-center, Open, Dose-escalation, and Expanded Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of JAB-21822 in Advanced Solid Tumors With KRAS p.G12C Mutation
Latest Information Update: 17 Jun 2024
At a glance
- Drugs Glecirasib (Primary)
- Indications Adenocarcinoma; Appendiceal cancer; Biliary cancer; Carcinoma; Cervical cancer; Colorectal cancer; Ductal carcinoma; Gastric cancer; Liver cancer; Mediastinal disorders; Non-small cell lung cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours
- Focus Adverse reactions; First in man; Registrational; Therapeutic Use
- Sponsors Jacobio Pharmaceuticals
- 12 Jun 2024 Planned number of patients changed from 144 to 311.
- 12 Jun 2024 Status changed from recruiting to active, no longer recruiting.
- 30 Apr 2024 Results published in the Jacobio Pharmaceuticals Media Release